Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics, Inc. (ELVN)
:ELVN
RESEARCH TOOLSreports
Holding ELVN?
Track your performance easily
ELVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.90 - $30.03
Previous CloseN/A
Volume37.78K
Average Volume (3M)216.08K
Market Cap
$1.05B
Enterprise Value$940.95M
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 13, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding48,859,165
10 Day Avg. Volume268,747
30 Day Avg. Volume216,081
Standard Deviation0.28
R-Squared0.03
Alpha-0.00237
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-21.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.21
Forecast
1Y Price Target
$39.00Price Target Upside81.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Enliven Therapeutics News
PremiumCompany Announcements
Enliven Therapeutics Reports Q3 Results and Clinical Progress
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageEnliven's highly selective and potentially best-in-class drugs for both CML and HER2+ breast cancer have generated significant investor interest in ELVN.
Market OpportunityEnliven's ELVN-001 is well-positioned to benefit as the 2L/2L+ CML market opens up with Scemblix migrating to a 1L setting.
Product DevelopmentEnliven Therapeutics is focusing on developing two small molecule kinase inhibitors with higher selectivity and cleaner safety profiles, addressing high unmet needs in CML and HER2 altered solid tumors.
Bears Say
Drug AdoptionSome patients on standard TKIs prefer not to change their current regimen, potentially affecting new drug adoption.
Investor SentimentShort interest in Enliven Therapeutics, Inc. is 23.4%.
Market CompetitionTERN-701 is seen as a direct competitor to ELVN-001, especially given its positive data in post-Scemblix treated patients.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics, Inc.’s price range in the past 12 months?
Enliven Therapeutics, Inc. lowest stock price was $10.90 and its highest was $30.03 in the past 12 months.
What is Enliven Therapeutics, Inc.’s market cap?
Enliven Therapeutics, Inc.’s market cap is $1.05B.
When is Enliven Therapeutics, Inc.’s upcoming earnings report date?
Enliven Therapeutics, Inc.’s upcoming earnings report date is Mar 13, 2025 which is in 50 days.
How were Enliven Therapeutics, Inc.’s earnings last quarter?
Enliven Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.497 by $0.017.
Is Enliven Therapeutics, Inc. overvalued?
According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued.
Does Enliven Therapeutics, Inc. pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
What is Enliven Therapeutics, Inc.’s EPS estimate?
Enliven Therapeutics, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has 48,859,165 shares outstanding.
What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?
Enliven Therapeutics, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.497. Following the earnings report the stock price went down -3.411%.
Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?
Among the largest hedge funds holding Enliven Therapeutics, Inc.’s share is Fairmount Funds Management Llc. It holds Enliven Therapeutics, Inc.’s shares valued at 82M.
---
Enliven Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.00 (81.65% Upside)
$39.00 (81.65% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 916.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
91.01%
12-Months-Change
Fundamentals
Return on Equity
-30.98%
Trailing 12-Months
Asset Growth
11.45%
Trailing 12-Months
Company Description
Enliven Therapeutics, Inc.
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
---
ELVN Stock 12 Month Forecast
Average Price Target
$39.00
▲(81.65% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Immunovant
―
Seres Therapeutics
―
Fulcrum Therapeutics
―
Ocugen
―
Sana Biotechnology
―
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
7/15 ratings generated profit
1 Year Average Return
+25.71%
reiterated a buy rating last month
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +25.71% per trade.
---